WhatsApp
backNews Article

Alkem Laboratories Reports Unaudited Consolidated Financial Results for Q2 and H1 FY2027 Ending September 30, 2026

Deloitte Haskins & Sells LLP reviews results including multiple international subsidiaries showing revenues over Rs.8,959 crore and net profit contributions for the period

Alkem Laboratories Limited announced its standalone and consolidated unaudited financial results for the quarter and half year ended September 30, 2026. The results, reviewed by Deloitte Haskins & Sells LLP, include contributions from multiple subsidiaries and an associate, reflecting total assets, revenues, profits, and cash flows for the period as per Indian Accounting Standard 34.

7 days ago|ALKEM+0.19%
Alkem Laboratories LimitedALkEMFinancial Results

Alkem Laboratories Limited

Financial Results

Alkem Laboratories Limited approved its standalone and consolidated unaudited financial results for the quarter and half year ended September 30, 2026, as reviewed by Deloitte Haskins & Sells LLP, covering the performance of its subsidiaries and associates in India and abroad.

The Board of Directors convened on November 12, 2026, to approve the unaudited financial results prepared under Indian Accounting Standard 34, including both standalone and consolidated figures for the stated periods.

The consolidated results reflect financial performance incorporating multiple subsidiaries such as S&B Holdings S.a.r.l and its subsidiaries in the USA, Pharmacor and its subsidiaries in Australia and Chile, Ascend Laboratories entities across South Africa, Germany, Malaysia and the Philippines, as well as associate companies.

The audit firm conducted a review engagement per applicable Indian standards and regulations, providing an unmodified conclusion that the results fairly represent the financial position and performance without material misstatements.

Five subsidiaries' interim financials were reviewed by other auditors and incorporated, showing total assets of Rs.15,803.8 million and revenues of Rs.6,013.9 million for the quarter, contributing net profits of Rs.401.6 million during the same period.

An additional 28 subsidiaries’ interim financials, which have not been reviewed by their auditors, were included based on management-certified results, reflecting total assets of Rs.11,605.5 million and revenues of Rs.1,661.7 million for the quarter with a net loss after tax of Rs.284.2 million owing partly to one associate's share of losses.

Highlights

  • Board meeting held on November 12, 2026, approved Q2 and H1 FY2027 unaudited results.
  • Consolidated revenues totaled Rs.8,959.0 million for H1 FY2027 across subsidiaries.
  • Net profit after tax from reviewed subsidiaries for Q2 reached Rs.401.6 million.
  • Included are subsidiaries and associates spanning USA, Australia, Chile, Germany, South Africa, Malaysia, and the Philippines.
  • Results prepared under Ind AS 34 and compliant with SEBI Listing Regulations.
  • Review completed by Deloitte Haskins & Sells LLP with no material misstatements reported.

Key Data Snapshot

Reporting periodQuarter and half year ended 30 September 2026
Consolidated total revenues for Q2Rs.6,013.9 million
Consolidated total revenues for H1Rs.8,959.0 million
Net profit after tax from 5 subsidiaries for Q2Rs.401.6 million
Net profit after tax from 5 subsidiaries for H1Rs.449.4 million
Total assets of 5 reviewed subsidiariesRs.15,803.8 million as at 30 September 2026
Total assets of 28 subsidiaries (not reviewed)Rs.11,605.5 million as at 30 September 2026
Net loss after tax from 28 subsidiaries for Q2Rs.284.2 million
Net loss after tax from 28 subsidiaries for H1Rs.384.9 million

What happened

  • Alkem Laboratories Ltd approved its standalone and consolidated unaudited financial results for Q2 and H1 FY2027 ending September 30, 2026.
  • The results cover activities of the parent entity, 33 subsidiaries, and one associate including international operations in USA, Australia, Chile, South Africa, Philippines, Germany, and Malaysia.
  • Deloitte Haskins & Sells LLP conducted an independent review in accordance with Indian standards and SEBI regulations with no adverse findings reported.
  • Financial disclosures provide a comprehensive snapshot of Alkem's performance and asset base as of the period end.

Key details

  • The consolidated revenue for Q2 FY2027 was Rs.6,013.9 million, with H1 total revenue at Rs.8,959.0 million for the reviewed subsidiaries.
  • Net profit after tax of Rs.401.6 million was recorded for Q2 by the five subsidiaries that were audited separately.
  • Twenty-eight additional subsidiaries' results were included based on management certifications, showing a net loss for the period due to certain associate contributions.
  • The consolidated results comply with Indian Accounting Standard 34 and SEBI Listing Obligations and Disclosure Requirements.
  • The audit review covered the Group, which includes the parent and subsidiaries, certified by Deloitte and other auditors where applicable.

Regulatory and governance context

  • The financial statements were prepared as per Ind AS 34 Interim Financial Reporting standard and comply with SEBI Listing Regulations, 2015.
  • The review was performed under SRE 2410 standards by Deloitte Haskins & Sells LLP, ensuring transparency and regulatory compliance.
  • The Board meeting lasted from 11:30 a.m. to 1:40 p.m. on November 12, 2026, when the results were approved and publicly disclosed.
  • The results, review reports and disclosures have been made available on the company's website.

More News on Financial Results

View all

Latest corporate announcements and market updates in Financial Results.

View all news
Alkem Laboratories Reports Unaudited Consolidated | Stockk News